PREMIER Biosoft International, a leading bioinformatics company, successfully completes the third and final phase of its software development project for DxTerity Diagnostics, Inc. to support their innovative NEAT technology.
Palo Alto, CA August 28, 2008 -PREMIER Biosoft International, a leading bioinformatics company, has recently started offering contract software development services. As a part of this service, PREMIER Biosoft International has successfully delivered the third and final phase of the software project for DxTerity Diagnostics.
DxTerity Diagnostics, a provider of genomic testing solutions, has developed NEAT, a genomic testing platform that replaces expensive enzymatic amplification techniques with a robust chemical reaction, enabling the development of simple and affordable diagnostic tests. NEAT has been successfully employed in the analysis of mRNA, microRNA, rRNA, and genomic DNA.
By providing a user-friendly software solution for the probe design needs of NEAT, DxTerity expects to lower barriers to customer adoption and speed the proliferation of this innovative technology. The software module allows customers to quickly adapt the NEAT technology to their individual needs, allowing the rapid development of robust genomic assays.
Our previous experience in developing high quality genomics design software gave us the expertise to handle the algorithms involved in this project. With this expertise and existing algorithms, we were able to complete the project in far less time than working from scratch. said Kay Brown, Vice President, Business Development, PREMIER Biosoft International.
The contract started in December 2007 and proceeded in phases with periodic deliveries until July 2008. After the initial requirements were provided by DxTerity, an extensive analysis was done by the PREMIER Biosoft team, consisting of a panel of domain experts and software engineers. The highlights of the project included developing the algorithms required for the analysis and designing the user interface for making the product both easy-to-use and comprehensive.
The scope of the project included designing a complete NEAT probe design module that adhered to the DxTerity probe design guidelines. For mutation specific probe design, algorithms were developed not only to reduce assay costs, but also to enable efficient mutation detection. This was achieved by designing the probe set such that one probe was common for the mutation and wild type detection.
"We decided to award this contract to PREMIER Biosoft International because of their considerable expertise in bioinformatics and the exceptional performance of their AlleleID software package in particular. The resulting software module streamlines the NEAT assay design process and allows our customers to quickly develop new genomic testing assays," says Bob Terbrueggen, President and CEO, DxTerity Diagnostics.
For details about the project, please visit: http://www.premierbiosoft.com/services/DxTerity.pdf
About PREMIER Biosoft International: Founded in 1994, the company is a group of computer scientists and molecular biologists dedicated to producing cutting edge intuitive software for the molecular biologist. The goal of the company is to study the most recent innovations in molecular biology and translate them into software products that aid biologists. Recently, the company has completed several custom software development contracts including one for PrimerDesign Ltd. Additional information about PREMIER Biosoft International can be found at http://www.PremierBiosoft.com
Contact: Arun Apte PREMIER Biosoft International 650-856-2703 http://www.PremierBiosoft.com
About DxTerity Diagnostics, Inc. DxTerity Diagnostics, a privately-held biotechnology company, is focused on the development of tools and methods that make genomic testing simple, affordable and accessible. These efforts led to the development of NEATTM, a genomic testing platform that eliminates the need for expensive and complicated enzymatic amplification procedure, and allows for direct analysis of many genomic targets. NEAT has been adapted for mRNA, microRNA, rRNA and genomic DNA applications.
